Paragon Bioservices
The CDMO has named Thomas VanCott, PhD, as chief technology and strategy officer (CTSO) – and made several other promotions and hires.
“Paragon’s contract development and biomanufacturing services have rapidly expanded and contributed significantly to the large increase in GMP-compliant gene and cell therapy products in clinical development today," VanCott told us.
"I will work to both continue this impressive growth trajectory as well as strategically enhance and augment our CMC services to meet the increasing market and complexity of innovate products being developed today."
VanCott previously spent 14 years as the president and CEO of Advanced Bioscience Laboratories (ABL) and served as a US Army Captain in the Medical Service Corps at Walter Reed Army Institute of Research.
Paragon also this month hired Chris Holmes, MBA, as vice president of facilities and engineering and Jim Gombold, PhD, as vice president of quality control and analytical development.
Randy Henrickson has been promoted to senior vice president of manufacturing, and Denise Krohn to vice president, quality assurance and compliance.
The new appointments follow the opening of a 200,000 square-foot facility and plans to hire more than 200 employees for the location.
Paragon CEO Pete Buzy previously told us, "There's also a significant deficit in gene therapy CDMO capacity that will mostly grow over the next three to five years. Paragon believes the space will increase by double digits in the foreseeable future."